NTP-PRAVASTATIN TABLET

দেশ: কানাডা

ভাষা: ইংরেজি

সূত্র: Health Canada

সক্রিয় উপাদান:

PRAVASTATIN SODIUM

থেকে পাওয়া:

TEVA CANADA LIMITED

এটিসি কোড:

C10AA03

INN (আন্তর্জাতিক নাম):

PRAVASTATIN

ডোজ:

10MG

ফার্মাসিউটিকাল ফর্ম:

TABLET

রচনা:

PRAVASTATIN SODIUM 10MG

প্রশাসন রুট:

ORAL

প্যাকেজ ইউনিট:

30/100

প্রেসক্রিপশন টাইপ:

Prescription

থেরাপিউটিক এলাকা:

HMG-COA REDUCTASE INHIBITORS

পণ্য সারাংশ:

Active ingredient group (AIG) number: 0122563001; AHFS:

অনুমোদন অবস্থা:

CANCELLED PRE MARKET

অনুমোদন তারিখ:

2017-06-13

পণ্য বৈশিষ্ট্য

PRODUCT MONOGRAPH
Pr
NTP-PRAVASTATIN
pravastatin sodium tablets
10, 20 and 40 mg
Lipid Metabolism Regulator
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario
Canada, M1B 2K9
Submission Control No: 166140
Date of Preparation:
July 23, 2013
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................. 3
SUMMARY PRODUCT INFORMATION
................................................................... 3
INDICATIONS AND CLINICAL USE
.........................................................................
3
CONTRAINDICATIONS
..............................................................................................
5
WARNINGS AND PRECAUTIONS
.............................................................................
5
ADVERSE REACTIONS
.............................................................................................
10
DRUG INTERACTIONS
.............................................................................................
14
DOSAGE AND ADMINISTRATION
.........................................................................
16
OVERDOSAGE
...........................................................................................................
17
ACTION AND CLINICAL PHARMACOLOGY
....................................................... 17
STORAGE AND STABILITY
.....................................................................................
19
PART II: SCIENTIFIC INFORMATION
................................................................... 21
PHARMACEUTICAL INFORMATION
.....................................................................
21
CLINICAL TRIALS
.....................................................................................................
22
DETAILED PHARMACOLOGY
................................................................................
28
TOXICOLOGY
............................................................................................................
29
REFERENCES
................................................